Saturday 17 October 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
262.03
5.90
−2.20%
Follow ILMN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
32.50 | 22.29 | 23.93 | 21.25 |
+8 more quarters Free account |
P/S ratio |
5.91 | 4.29 | 4.68 | 3.39 | |
P/FCF ratio |
28.99 | 19.67 | 22.19 | 14.75 | |
P/Operating CF |
132.09 | 65.26 | 63.33 | 51.16 | |
P/B ratio |
9.36 | 7.05 | 7.47 | 6.10 | |
Price to Tangible BV |
23.21 | 19.60 | 14.52 | 13.93 | |
EV/Sales |
6.09 | 4.48 | 4.76 | 3.44 | |
EV/EBITDA |
23.69 | 17.54 | 19.20 | 13.98 | |
EV/Operating CF |
24.99 | 17.45 | 19.16 | 13.13 | |
EV/FCF |
29.87 | 20.52 | 22.57 | 14.96 | |
Quick Ratio |
1.22 | 1.21 | 1.57 | 1.02 | |
Current Ratio |
1.80 | 1.75 | 2.08 | 1.43 | |
Net Debt/EBITDA |
1.03 | 1.21 | (0.53) | (0.97) | |
Debt/Assets |
22.42% | 22.72% | 22.43% | 16.09% | |
Debt/Equity |
0.53 | 0.56 | 0.55 | 0.42 | |
Asset Turnover |
0.71 | 0.69 | 0.67 | 0.70 | |
Operating CF/Net income |
0.97 | 2.16 | 0.96 | 1.89 | |
Capex/Depreciation |
(0.57) | (0.55) | (0.83) | (0.46) | |
Interest Coverage |
10.21 | 8.71 | 7.77 | 9.08 | |
Research and Development Expense of Revenue |
21.74% | 22.00% | 20.62% | 21.13% | |
Selling, General and Administrative Expense of Revenue |
23.55% | 24.93% | 26.57% | 25.55% | |
Intangible Assets out of Total Assets |
0.25 | 0.26 | 0.20 | 0.22 | |
Share Based Compensation of Revenue |
6.30% | 5.50% | 5.44% | 6.46% | |
Graham Net Nets |
(0.04) | (0.06) | (0.03) | (0.07) | |
Graham Number |
47.83 | 46.65 | 46.54 | 39.56 | |
Earnings Yield |
3.08% | 4.49% | 4.18% | 4.71% | |
Free Cash Flow Yield |
3.45% | 5.09% | 4.51% | 6.78% | |
Revenue per Share |
7.68 | 7.13 | 7.48 | 7.09 | |
Operating CF per Share |
1.33 | 1.89 | 2.07 | 1.86 | |
Capex per Share |
(0.26) | (0.25) | (0.35) | (0.20) | |
Free Cash Flow per Share |
1.07 | 1.64 | 1.72 | 1.65 | |
Cash per Share |
7.74 | 7.55 | 10.54 | 8.35 | |
Shareholders Equity per Share |
18.79 | 17.49 | 17.57 | 15.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.79 | 17.49 | 17.57 | 15.56 | |
Free Cash Flow |
161.00 | 251.00 | 266.00 | 253.00 | |
Working Capital |
1,256.00 | 1,172.00 | 1,704.00 | 834.00 | |
Capital Expenditures |
(40.00) | (38.00) | (55.00) | (31.00) | |
Net Current Asset Value |
(978.00) | (1,145.00) | (632.00) | (1,000.00) | |
EV/EBIT |
30.99 | 23.10 | 25.62 | 18.91 | |
Capex to Sales |
0.03 | 0.03 | 0.05 | 0.03 | |
Price to Operating Income |
30.07 | 22.13 | 25.19 | 18.65 | |
| Other line items | |||||
Average Receivables |
732.50 | 718.50 | 794.50 | 714.00 | |
Average Payables |
215.00 | 212.50 | 230.50 | 204.50 | |
Average Inventory |
602.00 | 574.00 | 555.50 | 582.00 | |
Average Assets |
6,368.50 | 6,370.50 | 6,473.50 | 6,095.50 | |
Average Common Equity |
2,548.00 | 2,522.00 | 2,548.00 | 2,253.00 |
Columns are period end dates